EHA 2024 | Clinical implications of extramedullary manifestations in CMML
Guillermo Montalban-Bravo, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the clinical implications of extramedullary manifestations in chronic myelomonocytic leukemia (CMML). He notes that CMML can affect the skin, lymph nodes, and other organs, with such involvement being associated with worse outcomes. Dr Montalban-Bravo emphasizes the importance of systematically characterizing these manifestations to improve treatment strategies and outcomes. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So, CMML is a disease that can involve not just the bone marrow sites, but also other tissues. For example, the skin quite frequently, but also lymph nodes and other organs. So, what we wanted to try and understand is a little bit better and characterize in a more systematic way patients with CMML that have this phenomenon. Reason being is because we observed that it’s associated with worse outcomes...
So, CMML is a disease that can involve not just the bone marrow sites, but also other tissues. For example, the skin quite frequently, but also lymph nodes and other organs. So, what we wanted to try and understand is a little bit better and characterize in a more systematic way patients with CMML that have this phenomenon. Reason being is because we observed that it’s associated with worse outcomes. So patients that do have these kind of infiltration of the skin or other organs tend to have worse outcome than patients that don’t. And what we found is that they’re associated also with RAS mutations particularly and they can be quite varied so it’s not like something that always appears in the same way. So the way the cells can kind of look in the sites that are involved can be different. So in some patients it looks more like monocytic involvement, in others it looks more like a disease called BPDCN which is a different entity. So our effort was to try and kind of evaluate and characterize that in a more systematic manner, to then try and see the overarching objective is, okay, if we understand this better can we develop strategies eventually to try and prevent it or treat it.
Read more...
Disclosures
Research support: Takeda Oncology, IFM Therapeutics, Solu Therapeutics.
